Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: DNTH

Dianthus Therapeutics, Inc.

Healthcare | Biotechnology

No licensed closing price on file for DNTH. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Dianthus Therapeutics, Inc. (NASDAQ: DNTH) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-19 23:11 UTC.

What Dianthus Therapeutics, Inc. does

The company is a clinical-stage biotechnology firm developing therapies for severe autoimmune diseases. Its lead candidate, claseprubart, is a monoclonal antibody designed to selectively inhibit the active form of the C1s complement protein, engineered for less frequent self-administered subcutaneous injections. A second candidate, DNTH212, is a bifunctional fusion protein targeting two immune pathways to address multiple autoimmune conditions.

Summarized from Dianthus Therapeutics, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Valuation
Return on equity-32.90%

Revenue, margins & earnings

FY2023: net loss $44M on revenue $3M$3MFY2023FY2024: net loss $85M on revenue $6M$6MFY2024FY2025: net loss $162M on revenue $2M$2MFY2025
  • Net income
  • Taxes & interest
  • Operating costs
  • Net loss year
Annual revenue; bands show net, operating margins · Open in Platform →

SEC Filings

SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-09-18
  • 2026-09-18CHIEF ACCOUNTING OFFICEROption exercise20,000$357.6K
  • 2026-09-18CHIEF ACCOUNTING OFFICERSale-6,771$686.4K
  • 2026-09-18CHIEF ACCOUNTING OFFICERSale-1,100$113.5K
Sign in to see all transactions →
Recent 8-K Events (parsed from SEC filings)All events →
Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

Company news

View all →

Questions this page answers

What does Dianthus Therapeutics, Inc. do?

The company is a clinical-stage biotechnology firm developing therapies for severe autoimmune diseases.

When did DNTH last file with the SEC?

Dianthus Therapeutics, Inc.'s most recent SEC filing on record is a 8-K filed 2026-06-12. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings, with the company profile (sector, industry, exchange) from public data providers, fetched 2026-10-19 23:11 UTC. This page is also available as JSON at /api/data?ticker=DNTH and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for DNTH and 5,000+ tickers.

Create a free account — keep DNTH
For your agent
GET /api/data?ticker=DNTH

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt